Coherus Oncology reported Q2 2026 results showing continuing investment in commercial launch and clinical pipeline expansion, centered around LOQTORZI, its sole approved product. Despite growing revenues from LOQTORZI, the company continues to run net losses amidst significant R&D spending on mid-stage candidates and combination trials. Coherus operates in a highly competitive oncology biologics environment that demands effective market access execution and clinical progress. Its financial profile reflects ongoing capital needs supported by recent equity raises and a balanced cash runway over the next year.